- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06955169
Estudo de [177LU] Lu-dotatato em adultos com Meningioma de Meningioma Progressivo Intracraniano Grau 1-3 (MOMENTUM-1)
Momentum-1: um estudo multicêntrico, randomizado, aberto e de fase II de [177LU] Lu-dotatato em adultos com Meningioma de grau 1-3 progressivo de grau intracraniano 1-3
This is an open-label, multicenter, randomized, phase 2 clinical study to evaluate the efficacy of [177Lu]Lu-DOTATATE in patients with progressive grade 1-3 intracranial meningioma.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Study participants will be randomized by a 2:1 ratio to receive either [177Lu]Lu-DOTATATE or standard of care therapy as deemed appropriate by the local investigator. At time of progression, participants on the standard of care arm may cross-over to the [177Lu]Lu-DOTATATE alternative treatment arm.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 2
Contactos e Locais
Contato de estudo
- Nome: Sylvia C Kurz, MD,PhD
- Número de telefone: 203-785-5616
- E-mail: Sylvia.Kurz@yale.edu
Locais de estudo
-
-
California
-
Irvine, California, Estados Unidos, 92697
- Recrutamento
- University of California, Irvine
-
Investigador principal:
- Daniela Bota, MD, PhD
-
Contato:
- Manisha Dandekar
- E-mail: mdandeka@hs.uci.edu
-
La Jolla, California, Estados Unidos, 92093
- Recrutamento
- University of California San Diego - Moores Cancer Center
-
Investigador principal:
- Jona Hattangadi-Gluth, MD
-
Contato:
- Mohammad Amjad
- E-mail: mtamjad@health.ucsd.edu
-
Los Angeles, California, Estados Unidos, 90033
- Recrutamento
- USC Keck School of Medicine
-
Contato:
- Christine Duran
- E-mail: duran_c@med.usc.edu
-
Investigador principal:
- Aram Modrek, MD, PhD
-
-
Connecticut
-
New Haven, Connecticut, Estados Unidos, 06520
- Recrutamento
- Yale University
-
Investigador principal:
- Sylvia Kurz, MD, PhD
-
Contato:
- Amy Rodrigues, CCRC
- Número de telefone: 203-260-9632
- E-mail: amy.rodrigues@yale.edu
-
-
Florida
-
Jacksonville, Florida, Estados Unidos, 32207
- Recrutamento
- Baptist MD Anderson Cancer Center
-
Investigador principal:
- Michael Olson, MD PhD
-
Contato:
- E-mail: CTOinterest@bmcjax.com
-
Subinvestigador:
- Andre Alvarez, MD PhD
-
Miami, Florida, Estados Unidos, 33146
- Recrutamento
- University of Miami
-
Contato:
- Lily Friedman
- E-mail: lxf699@med.miami.edu
-
Investigador principal:
- Marina Kushnirsky, MD
-
Miami, Florida, Estados Unidos, 33176
- Recrutamento
- Baptist Health Medical Group Oncology
-
Investigador principal:
- Matthew Hall, MD
-
Contato:
- Nicolas Morales
- E-mail: nicolas.morales1@baptisthealth.net
-
Tampa, Florida, Estados Unidos, 33543
- Recrutamento
- Moffitt Cancer Center
-
Contato:
- Abdullah Abdelkawy
- E-mail: Abdullah.abdelkawy@Moffitt.org
-
Investigador principal:
- Andre Luiz Beer Furlan, MD, PhD
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30318
- Recrutamento
- Piedmont Healthcare
-
Contato:
- Jeff Whorton, BSN,RN
- E-mail: jeff.whorton@piedmont.org
-
Investigador principal:
- Adam Nowlan, MD, MPH
-
-
Indiana
-
Indianapolis, Indiana, Estados Unidos, 46202
- Recrutamento
- Indiana University
-
Investigador principal:
- Kathryn Nevel, MD
-
Contato:
- Lauren Perrey-Moore, RN
- E-mail: lperry@iu.edu
-
-
Iowa
-
Iowa City, Iowa, Estados Unidos, 52242
- Recrutamento
- University of Iowa Health Care
-
Contato:
- Kristin West, RN, BSN
- E-mail: kristin-gaimari-varner@uiowa.edu
-
Investigador principal:
- Kristin Plichta, MD, PhD
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02215
- Recrutamento
- Dana-Farber/Harvard Cancer Center
-
Contato:
- Kathryn Partridge
- E-mail: Kathryn_Partridge@DFCI.HARVARD.EDU
-
Investigador principal:
- Gilbert Youssef, MD
-
-
Michigan
-
Ann Arbor, Michigan, Estados Unidos, 48109
- Recrutamento
- University of Michigan Rogel Cancer Center
-
Contato:
- Jen Thomas
- E-mail: jennifkt@med.umich.edu
-
Investigador principal:
- Sean Miller, MD
-
Detroit, Michigan, Estados Unidos, 48202
- Recrutamento
- Henry Ford Hospital
-
Contato:
- Jennifer Cooper
- E-mail: jcoope13@hfhs.org
-
Investigador principal:
- Tobias Walber, MD, PhD, MPH
-
-
New York
-
New York, New York, Estados Unidos, 10016
- Recrutamento
- NYU Lagone Health
-
Investigador principal:
- Marissa Barbaro, MD
-
Contato:
- Olga Garduno-Ortega
- E-mail: Olga.Garduno-Ortega@nyulagone.org
-
-
North Carolina
-
Durham, North Carolina, Estados Unidos, 22708
- Recrutamento
- Duke University Medical Center
-
Investigador principal:
- Margaret Johnson, MD
-
Contato:
- Kelly Moulton
- E-mail: kelly.moulton@duke.edu
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19107
- Recrutamento
- Thomas Jefferson University Hospital
-
Investigador principal:
- Iyad Alnahhas, MD
-
Contato:
- Oleksandr Kolesnikov
- Número de telefone: 215-600-9151
- E-mail: ONCTrialNow@jefferson.edu
-
-
Texas
-
Houston, Texas, Estados Unidos, 77030
- Recrutamento
- MD Anderson Cancer Center
-
Contato:
- Wathoo Chetna
- E-mail: cwathoo@mdanderson.org
-
Investigador principal:
- Carlos Kamiya-Matsuoka, MD
-
-
Wisconsin
-
Milwaukee, Wisconsin, Estados Unidos, 53226
- Recrutamento
- Medical College of Wisconsin
-
Contato:
- Bailee Fritz
- E-mail: bfritz@mcw.edu
-
Investigador principal:
- Michael Straza, MD
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
STEP 1 REGISTRATION
- Aged >= 18 years
- Histologically confirmed diagnosis of WHO grade 1-3 meningioma
- Disease progression following at least one prior surgical intervention (biopsy or resection) and at least one prior course of radiation.
- The patient is not considered a candidate for additional surgery and/or radiation or the patient has declined additional surgery and/or radiation.
- Presence of measurable contrast-enhancing disease on gadolinium-enhanced MRI brain scan defined as at least one lesion with two perpendicular diameters measuring ≥10 mm on two or more axial slices (≤ 5 mm interslice thickness, ≤ 1 mm interslice gap) per current RANO meningioma criteria
- Progression of disease determined by local radiology review per current RANO meningioma criteria, defined as:
- ≥ 15% increase in sum of product of perpendicular measurements of up to 5 measurable target lesions within the last 6 months (196 days), or
- ≥ 25% increase in sum of product of perpendicular measurements of up to 5 measurable target lesions within the last 12 months (379 days), or
- Development of a new measurable lesion
- The following scans must be available for submission for central radiology review:
- Pre-progression gadolinium-enhanced MRI brain scan no older than 12 months (379 days) that serves as a reference for evaluation of radiographic disease progression
- Progression gadolinium-enhanced MRI brain scan
STEP 2 REGISTRATION
- Progression of disease determined by central radiology review per current RANO meningioma criteria, defined as:
- ≥ 15% increase in sum of product of perpendicular measurements of up to 5 measurable target lesions within the last 6 months (196 days), or
- ≥ 25% increase in sum of product of perpendicular measurements of up to 5 measurable target lesions within the last 12 months (379 days), or
- Development of a new measurable lesion.
- [68Ga]Ga-DOTATATE uptake on PET-CT. Positive uptake is defined as uptake at least as high as liver, based on the uptake in at least one target lesion.
- Both the patient and investigator must agree that the patient will NOT receive SSTR2-targeted therapy, surgical resection, or radiation therapy until progression of disease while on study treatment.
- Patients must be willing and able to undergo regular MRI scans of the brain and [68Ga]Ga-DOTATATE PET-CT imaging during the study.
- Patients must have recovered to CTCAE grade ≤1 or pretreatment baseline from clinically significant adverse events related to prior therapy (exclusions include alopecia, lymphopenia, sensory neuropathy ≤ grade 2, or other ≤ grade 2 not constituting a safety risk based on the investigator's judgment).
- Adequate organ and bone marrow function as defined below (within 28 days prior to step 2 registration):
- Absolute neutrophil count (ANC) ≥ 1500/mm3
- Platelet count ≥ 75,000/mm3
- Hemoglobin ≥ 8 g/dL
- Creatinine clearance (calculated by the Cockroft-Gault method) ≥40mL/min
- AST (SGOT) and ALT (SGPT) ≤ 3 x the laboratory upper limit of normal (ULN)
- Total serum bilirubin ≤ 3 x ULN (except participants with Gilbert's Syndrome, who can have a total bilirubin ≤ 5 x ULN)
- Potassium within normal limits.
Exclusion Criteria:
- Patients with a clinical diagnosis of NF2-related schwannomatosis or with a known molecular diagnosis of NF2-related schwannomatosis.
- Patients with radiation-associated meningiomas.
- Patients with known intraspinal meningiomas or meningioma metastases outside the skull/spinal column. Meningiomas invading the skull base or orbits are not excluded.
- Prior SSTR2-targeted therapy, e.g. Somatostatin LAR or short-acting Octreotide. No limit on number of prior non-SSTR2-tartgeted systemic therapies.
- Unstable neurological symptoms requiring steroids to control symptoms at a dose of >2 mg of dexamethasone (or equivalent) daily within 28 days prior to step 2 registration.
- Patients requiring immediate local therapy (e.g. surgical resection).
- Surgical procedure within the timeframes listed below, prior to step 2 registration.
- 28 days from any prior craniotomy
- 7 days from stereotactic biopsy Note: There is no limit to the number of prior surgical interventions
- Treatment within the timeframes specified below, prior to step 2 registration.
- 28 days (or 5 half-lives, whichever is longer) for cytotoxic chemotherapy, biologic agent, investigational agent or any other systemic agent prescribed for the purpose of treating meningioma
- 6 weeks from nitrosoureas Note: There is no limit to the number of prior systemically administered therapeutic agents.
- A target lesion is excluded if it has received any of the following:
- More than 2 total prior courses of radiation
- More than 1 prior course of standard fractionated external beam radiation therapy (EBRT)
- Radiation treatment to the target lesion completed <24 weeks (168 days) before Step 2 registration.
For purposes of this criterion, one course of EBRT counts as one course regardless of duration, and each course of stereotactic radiation (1-5 fractions) counts as one course. Accordingly, a target lesion may have received at most one prior course of EBRT plus one prior course of stereotactic radiation, or two prior courses of stereotactic radiation. Prior radiation history must be evaluated on a lesion-by-lesion basis, including radiation delivered before any subsequent surgical resection.
- All types of radioligand therapy at any time prior to registration. Radioligands received for diagnostic purposes are not exclusionary.
- Known hypersensitivity to somatostatin analogues or any component of the [68Ga]Ga- DOTATATE or [177Lu]Lu-DOTATATE formulations.
- Active infection requiring current use of intravenous therapy with antibiotics.
- Active cardiovascular disease: cerebral vascular accident/stroke (≤ 6 months prior to registration), myocardial infarction (≤ 6 months prior to registration), congestive heart failure (≥ NYHA class II), unstable angina pectoris, or serious cardiac arrhythmia requiring medication.
- An active malignancy ≤ 3 years. Note: Patients with a malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
- Pregnant and/or breastfeeding patients who are unwilling to discontinue breast feeding.
- Participants of childbearing potential must have a negative pregnancy test within 14 days of study entry.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: [177Lu]Lu-DOTATATE
Study participants receive [177Lu]Lu-DOTATATE |
The treatment regimen consists of 4 (+2 optional) administrations of [177Lu]Lu-DOTATATE. The recommended interval between infusions is 4 weeks (+ 7 days).
Outros nomes:
|
|
Outro: Control
Study participants receive systemic Standard of Care (SOC) Therapy. Control Arm participants crossover to [177Lu]Lu-DOTATATE at progression |
Treatments will occur at the discretion and based on clinical judgement of the local and treating investigator. Systemic SOC therapy with one of the following agents: bevacizumab, everolimus, or sunitinib.
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Progression Free Survival (PFS)
Prazo: Assessed up to 4 years
|
Proportion of patients alive without disease progression per current RANO meningioma criteria |
Assessed up to 4 years
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Progression free survival at 6 months (PFS-6)
Prazo: 6 months
|
Proportion of participants alive without progression at 6 months assessed per RANO meningioma criteria |
6 months
|
|
Overall Survival at 12 months (OS-12)
Prazo: 12 months
|
Proportion of participants alive at 12 months |
12 months
|
|
Overall survival (OS)
Prazo: Assessed up to 4 years
|
Proportion of patients after cross-over alive without disease progression per current RANO meningioma criteria |
Assessed up to 4 years
|
|
Progression-free Survival after cross-over (PFS2)
Prazo: Assessed up to 4 years
|
Time from cross-over to disease progression per RANO meningioma criteria or death from any cause, whichever occurs first. |
Assessed up to 4 years
|
|
Disease Control Rate (DCR)
Prazo: Assessed up to 4 years
|
Proportion of patients achieving complete response, partial response, minor response or stable disease as per RANO meningioma criteria |
Assessed up to 4 years
|
|
Objective response rate (ORR)
Prazo: Assessed up to 4 years
|
Proportion of patients achieving complete or partial response as per RANO meningioma criteria. |
Assessed up to 4 years
|
|
Number of participants by highest grade treatment-emergent adverse event (TEAE):
Prazo: Assessed up to 4 years
|
Number of participants experiencing the highest grade TEAE, graded according to CTCAE version 5.0 (Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = life-threatening, Grade 5 = death related to adverse event). |
Assessed up to 4 years
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Sylvia C Kurz, MD, PhD, Yale University
- Investigador principal: Erik P Sulman, MD,PhD, Duke University
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças do Sistema Nervoso
- Neoplasias por local
- Neoplasias
- Neoplasias por Tipo Histológico
- Neoplasias, Tecido Nervoso
- Neoplasias do Sistema Nervoso
- Neoplasias, Tecido Vascular
- Neoplasias Meníngeas
- Neoplasias do Sistema Nervoso Central
- Meningioma
- Aminoácidos, peptídeos e proteínas
- Proteínas
- Produtos químicos orgânicos
- Compostos heterocíclicos, 1 anel
- Compostos heterocíclicos
- Compostos heterocíclicos, 2 anel
- Compostos heterocíclicos, anel fundido
- Azoles
- Indoles
- Anticorpos, monoclonais, humanizados
- Anticorpos, monoclonais
- Anticorpos
- Imunoglobulinas
- Imunoproteínas
- Proteínas sanguíneas
- Globulinas de soro
- Globulins
- Macrolídeos
- Lactonas
- Pirróis
- Sirolimus
- Sunitinibe
- Bevacizumabe
- Everolimo
- Lutetium lu 177 dotatato
Outros números de identificação do estudo
- RTOG 3523
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .